Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triprilumab
- Development stage
- Phase 2
- Lead developer
- Kelun-Biotech
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Triprilumab (SKB336) is a novel trispecific monoclonal antibody developed by Kelun-Biotech. It is designed to simultaneously target three key pathways in the tumor microenvironment: programmed death-ligand 1 (PD-L1), cluster of differentiation 47 (CD47), and 4-1BB (CD137). By blocking the PD-1/PD-L1 and CD47/SIRPα "don't eat me" signals while providing agonistic stimulation to the 4-1BB costimulatory receptor on T cells and NK cells, triprilumab aims to enhance both innate and adaptive anti-tumor immune responses. This multi-pronged approach is intended to overcome resistance to traditional checkpoint inhibitors and improve efficacy in patients with advanced solid tumors.
- Other names
- triprilumab
02
Targets
CD47 (Cluster of Differentiation 47)TNFRSF9 (CD137 extracellular domain)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on triprilumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triprilumab.